$TERNTerns Pharmaceuticals, Inc.

📅 Upcoming

🕒 Recent(90d)

News

• Trend of women-led M&A fades in 2026 with just two deals so far
  Last year, 11 major M&A deals were signed with women-led biotechs. The industry is nowhere near on track to meet that bar for 2026.
  biospace · 5d ago
• BMS CEO Boerner doesn’t ‘feel any compulsion to chase deals’ despite lack of M&A this year
  BMS may have been absent from the dealmaking spree of some of its Big Pharma peers this year, but that might not change anytime soon.
  fiercebiotech · 2mo ago
• Veradermics declares first efficacy win in women for hair loss drug
  Veradermics is for the first time reporting positive efficacy of its oral formulation of minoxidil in female pattern hair loss, which broadens the market potential of its flagship asset. In a mid-s…
  endpoints · 2mo ago
• J&J looks to widen Imaavy’s use; $300M backs rare disease drug launch
  New data suggest Imaavy could be an effective treatment for autoimmune anemia. Elsewhere, Enliven detailed data for a Merck leukemia rival and MBX hyperparathyroidism drug hit its goal.
  biopharma_dive · 3mo ago
• Lilly, Gilead lead pharma’s M&A boom
  Deal volume in 2026 is substantially outpacing last year, and activity is being driven by interest in cancer and autoimmune disease drugs.
  biopharma_dive · 4mo ago
• Merck still sees ‘compelling’ outlook for Terns leukemia drug
  Despite updated study data that suggest Terns’ treatment may be less differentiated, company executives claimed Thursday that it still could be an important step forward in care.
  biopharma_dive · 5mo ago